开发视觉计算的SUVmean(HIT评分)用于筛选PSMA PET/CT预测177Lu-PSMA治疗反应:与定量SUVmean及患者结局的比较
本研究基于139例转移性去势抵抗性前列腺癌患者的68Ga-PSMA-11 PET/CT数据,开发了一种结合肿瘤异质性与强度的4分类视觉评分(HIT评分),无需定量软件即可评估SUVmean相关要素。HIT评分与PSA50应答、PSA-PFS和OS相关,读者间一致性κ为0.71,与定量SUVmean作为预后工具相当。
要点
- HIT评分1-4分的PSA50分别为0%、39%、65%和76%。
- HIT评分与PSA-PFS和OS相关(log-rank检验P<0.001和P=0.002)。
- HIT评分读者间一致性Cohen κ为0.71。
核心结论
- 结合肿瘤异质性与强度的前列腺特异性膜抗原PET/CT评分(HIT评分)与定量SUVmean作为177Lu-PSMA治疗后的预后工具相当。
研究设计与样本
- 研究纳入经伦理批准的试验中转移性去势抵抗性前列腺癌患者的数据集,这些患者在接受雄激素受体信号抑制和紫杉烷化疗(或不适合紫杉烷)后接受177Lu-PSMA-617和177Lu-PSMA I&T治疗,治疗前进行68Ga-PSMA-11 PET/CT筛查。
- 共分析139例参与者的数据,对所有参与者的筛查68Ga-PSMA-11 PET/CT进行半定量和视觉分析。
主要发现
- 75例(54%)患者达到PSA50,中位PSA-PFS为5.5个月(95%CI,4.1-6.0个月),OS为13.5个月(95%CI,11.1-17.9个月)。
- SUVmean作为连续变量或四分位数分析时与PSA50和生存结局相关。
- HIT评分1-4分的PSA50分别为0%、39%、65%和76%。
- HIT评分与PSA-PFS和OS强烈相关(log-rank检验,P<0.001和P=0.002)。
- HIT评分1-4分的中位PSA-PFS分别为1.0、4.1、6.0和8.5个月,中位OS分别为7.6、12.0、18.5和16.9个月。
关键数值与推荐
- 视觉分析包括二元视觉异质性评估(均匀或不均匀),并分配肿瘤SUVmax范围(<15、15-29、30-49、50-79或≥80)。
- HIT评分1分:SUVmax<15;评分2分:SUVmax 15-79且强度不均匀;评分3分:SUVmax 15-79且强度均匀;评分4分:SUVmax≥80。
- HIT评分读者间Cohen κ为0.71。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
177Lu-PSMA therapy is an effective treatment in patients with metastatic castration-resistant prostate cancer. SUVmean is a valuable screening biomarker to assess the suitability for 177Lu-PSMA therapy but requires quantitative software. This study aims to develop a simple, clinically applicable prostate-specific membrane antigen PET/CT score that encompasses the elements of SUVmean without requiring additional quantification. Methods: Datasets from ethics-approved trials of patients with metastatic castration-resistant prostate cancer after androgen receptor signaling inhibition and taxane chemotherapy (or unfit for taxane), who were treated with 177Lu-PSMA-617 and 177Lu-PSMA I&T with a pretreatment screening with 68Ga-PSMA-11 PET/CT, and clinical outcome data, including a prostate-specific antigen (PSA) 50% response rate (PSA50), PSA progression-free survival (PSA-PFS), and overall survival (OS), were included. The screening 68Ga-PSMA-11 PET/CT of all participants was analyzed both semiquantitatively and visually. Semiquantitative analysis was used to derive the SUVmean Visual analysis of the 68Ga-PSMA-11 PET/CT images involved a binary visual heterogeneity assessment (homogeneous or heterogeneous), allocating a tumor SUVmax range (<15, 15-29, 30-49, 50-79, or ≥80). A 4-category score incorporating both heterogeneity and intensity of tumors (HIT) was then developed as a combination of heterogeneity and intensity (SUVmax range). The SUVmax was less than 15 for score 1, 15-79 with heterogeneous intensity for score 2, 15-79 with homogeneous intensity for score 3, and 80 or greater for score 4. This score was evaluated according to clinical outcomes (PSA50, PSA-PFS, and OS) and compared with SUVmean Results: Data from 139 participants were analyzed. In total, 75 (54%) patients achieved a PSA50 with a median PSA-PFS of 5.5 mo (95% CI, 4.1-6.0 mo) and an OS of 13.5 mo (95% CI, 11.1-17.9 mo). SUVmean was associated with PSA50 and survival outcomes when analyzed as a continuous variable or as quartiles. The PSA50 for HIT scores 1-4 was 0%, 39%, 65%, and 76%, respectively. The HIT score was strongly related to PSA-PFS and OS (log-rank test, P < 0.001 and P = 0.002). The median PSA-PFS for HIT scores 1-4 was 1.0, 4.1, 6.0, and 8.5, respectively, and the median OS was 7.6, 12.0, 18.5, and 16.9 mo, respectively. Cohen κ between readers for the HIT score was 0.71. Conclusion: A prostate-specific membrane antigen PET/CT score incorporating HIT derived from tools on a standard PET workstation is comparable with quantitative SUVmean as a prognostic tool following 177Lu-PSMA therapy.
引用
- Swiha M, Papa N, Sabahi Z, et al. Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177Lu-PSMA Therapy: Comparison with Quantitative SUVmean and Patient Outcomes. J Nucl Med. 2024. PMID: 38637137. doi:10.2967/jnumed.123.267014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。